KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities: 2009-2025

Historic Total Non-Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Sep 2025 value amounting to $4.2 billion.

  • Alnylam Pharmaceuticals' Total Non-Current Liabilities rose 9.51% to $4.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 9.51%. This contributed to the annual value of $3.8 billion for FY2024, which is 1.01% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Total Non-Current Liabilities stood at $4.2 billion, which was up 6.91% from $3.9 billion recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Non-Current Liabilities peaked at $4.2 billion during Q3 2025, and registered a low of $2.3 billion during Q1 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $3.7 billion (2023), whereas its average is $3.7 billion.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 146.40% in 2021, and later fell by 1.28% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $3.0 billion in 2021, then climbed by 18.13% to $3.5 billion in 2022, then increased by 7.16% to $3.7 billion in 2023, then climbed by 1.01% to $3.8 billion in 2024, then climbed by 9.51% to $4.2 billion in 2025.
  • Its last three reported values are $4.2 billion in Q3 2025, $3.9 billion for Q2 2025, and $3.7 billion during Q1 2025.